Patients with cancer have a higher risk of severe coronavirus disease (COVID-19) and
associated mortality than the general population. Owing to this increased risk, patients with …

Seroprevalence surveys suggest that more than a third and possibly more than half of the
global population has been infected with SARS-CoV-2 by early 2022. As large numbers of …

Objective There is an urgent need to assess the impact of immunosuppressive therapies on
the immunogenicity and efficacy of SARS-CoV-2 vaccination. Methods Serological and T …

Introduction A precise estimate of the frequency and severity of SARS‐CoV‐2 reinfections
would be critical to optimize restriction and vaccination policies for the hundreds of millions …

We systematically reviewed studies to estimate the risk of SARS-CoV-2 reinfection among
those previously infected with SARS-CoV-2. For this systematic review, we searched …

Introduction There is an increasing body of evidence surrounding the importance of a T cell-
mediated response to SARS-CoV-2 infection and after COVID-19 vaccination. In this internal …

Summary SARS-CoV-2 primary strain-based vaccination exerts a protective effect against
Omicron variants-initiated infection, symptom occurrence, and disease severity in a booster …

Background Immunocompromised (IC) patients are at higher risk of severe SARS-CoV-2
infection, morbidity, and mortality compared to the general population. They should be …

Relationships between viral load, severity of illness, and transmissibility of virus are
fundamental to understanding pathogenesis and devising better therapeutic and prevention …

Immunocompromised individuals and particularly those with hematologic malignancies are
at increased risk for SARS-CoV-2-associated morbidity and mortality due to immunologic …